<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinical Trial Emulation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/clinical-trial-emulation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 13:38:21 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Clinical Trial Emulation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Revolutionary AI Platform Pinpoints Patients Most Likely to Gain from Clinical Trials</title>
		<link>https://bioengineer.org/revolutionary-ai-platform-pinpoints-patients-most-likely-to-gain-from-clinical-trials/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 08 Jan 2025 23:24:11 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Artificial intelligence in oncology]]></category>
		<category><![CDATA[Clinical Trial Emulation]]></category>
		<category><![CDATA[machine learning applications]]></category>
		<category><![CDATA[Patient Risk Stratification]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionary-ai-platform-pinpoints-patients-most-likely-to-gain-from-clinical-trials/</guid>

					<description><![CDATA[A groundbreaking study spearheaded by the Winship Cancer Institute of Emory University in conjunction with the Abramson Cancer Center of the University of Pennsylvania has unveiled an innovative artificial intelligence (AI) platform that stands poised to revolutionize the way clinicians and patients evaluate the potential benefits of therapies under investigation in clinical trials. This cutting-edge [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233404</post-id>	</item>
	</channel>
</rss>
